Telix Pharmaceuticals Limited (NASDAQ:TLX) Stock Has Average Target Price of $20.50

Telix Pharmaceuticals Limited (NASDAQ:TLX) has received a consensus rating of “Moderate Buy” from the five brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $20.50.

A number of research firms have issued reports on TLX. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. Wedbush reissued an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Wednesday, October 21st. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Friday, September 25th. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, September 21st. Finally, Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th.

Telix Pharmaceuticals Stock Performance

NASDAQ:TLX opened at $9.15 on Friday. The stock’s 50 day moving average price is $11.34 and its 200 day moving average price is $10.79. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $13.11. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. Lazard Asset Management LLC raised its holdings in Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after buying an additional 39,400 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Telix Pharmaceuticals in the second quarter worth about $1,731,000. Private Advisor Group LLC boosted its stake in shares of Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after acquiring an additional 128,070 shares in the last quarter. XY Capital Ltd boosted its stake in shares of Telix Pharmaceuticals by 468.0% during the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after acquiring an additional 58,739 shares in the last quarter. Finally, WoodTrust Financial Corp bought a new stake in shares of Telix Pharmaceuticals during the 3rd quarter worth about $186,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company’s principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.